Topical antibiotics prophylaxis for infections of indwelling pleural/peritoneal catheters (TAP‐IPC): A pilot study

Abstract Background and Objective Indwelling pleural catheter (IPC) and indwelling peritoneal catheter (IPeC) have established roles in the management of malignant pleural and peritoneal effusions but catheter‐related infections remain a major concern. Topical mupirocin prophylaxis has been shown to reduce peritoneal dialysis catheter infections. This study aimed to assess the (i) compatibility of IPC with mupirocin and (ii) feasibility, tolerability and compliance of topical mupirocin prophylaxis in patients with an IPC or IPeC. Methods (i) Three preparations of mupirocin were applied onto segments of IPC thrice weekly and examined with scanning electron microscope (SEM) at different time intervals. (ii) Consecutive patients fitted with IPC or IPeC were given topical mupirocin prophylaxis to apply to the catheter exit‐site following every drainage/dressing change (at least twice weekly) and followed up for 6 months. Results (i) No detectable structural catheter damage was found with mupirocin applied for up to 6 months. (ii) Fifty indwelling catheters were inserted in 48 patients for malignant pleural ( n = 41) and peritoneal ( n = 9) effusions. Median follow‐up was 121 [median, IQR 19–181] days. All patients tolerated mupirocin well; one patient reported short‐term local tenderness. Compliance was excellent with 95.8% of the 989 scheduled doses delivered. Six patients developed catheter‐related pleural ( n = 3), concurrent peritoneal/local ( n = 1) and skin/tract ( n = 2) infections from Streptococcus mitis (with Bacillus species or anaerobes), Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa. Conclusion This first study of long‐term prevention of IPC‐ or IPeC‐related infections found topical mupirocin prophylaxis feasible and well tolerated. Its efficacy warrants future randomized studies.